Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies
American Journal of Hematology · 2025-05 · 100 (5) · 758-769
DOI: 10.1002/ajh.27628 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 08.02.2025. Verfasst von Jayastu Senapati und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neoplasms, Second Primary. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of Texas MD Anderson Cancer Center, University of Texas MD Anderson SPORE.
Abstract (Originalsprache)
Ontogeny of acute myeloid leukemia (AML) provides prognostic information, however closer interrogation with respect to AML characteristics, genomics, and various treatments are warranted. We defined untreated clinical secondary (CS) AML as AML with a diagnosis of antecedent myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MDS‐MPN) without exposure to hypomethylating agents or chemotherapy; genomic secondary (GS) AML included patients with myelodysplasia related cytogenetics (MRC) or myelodysplasia related mutations (MRM) without a known antecedent myeloid neoplasm or prior chemo‐radiotherapy for non‐myeloid neoplasms. Among newly diagnosed AML patients classified as untreated CS‐AML ( n = 133) or GS‐AML ( n = 389), median relapse‐free survival (RFS) (11.9 vs. 12.4 months, p = 0.36) and overall survival (OS) (11.6 vs. 14.4 months, p = 0.75) were similar. No difference in RFS and OS between these groups treated with low‐intensity therapy (LIT) and venetoclax regimens was seen, but both were inferior to de novo (DN) AML without secondary‐type genomics (pure DN‐AML). GS‐AML defined by the presence of only MRM had superior OS compared with MRM ± MRC with LIT+ venetoclax therapy (RFS 19.5 vs. 6.8 months [ p < 0.01] and OS 29.6 vs. 8.4 [ p < 0.01]) and had similar RFS (29.8 months, p = 0.48) and OS (32.0 months, p = 0.48) to pure DN‐AML treated with LIT+ venetoclax. On multivariate analysis in patients treated with LIT+ venetoclax, untreated CS‐AML (vs. GS‐AML), adverse cytogenetics and ELN 2024 adverse‐risk disease (mutated TP53 ) were associated with higher hazard of death. Adverse cytogenetics was the strongest prognostic variable predicting survival. Mutation‐driven genomic ontogeny of newly diagnosed AML with MRM appears less prognostic than cytogenetic‐driven ontogeny with venetoclax‐based therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Departmnet of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Jayastu Senapati, Sanam Loghavi, Jennifer Marvin-Peek, Guillermo Garcia-Manero, Tapan M Kadia, Gautam Borthakur, Naval Daver, Nicholas J Short, Nitin Jain, Ghayas C Issa, Fadi Haddad, Kelly Chien, Guillin Tang, Beenu Thakral, Guillermo Montalban-Bravo, Naveen Pemmaraju, Alexandre Bazinet, Mahesh Swaminathan, Hussein A Abbas, Patrick Reville, Uday Popat, Elias Jabbour, Farhad Ravandi, Hagop M Kantarjian, Courtney D DiNardo
Förderung
- NCI NIH HHS
- University of Texas MD Anderson Cancer Center
- University of Texas MD Anderson SPORE
Zitieren
APA
Senapati, J., Loghavi, S., Marvin-Peek, J., Garcia-Manero, G., Kadia, T. M., Borthakur, G., Daver, N., Short, N. J., Jain, N., Issa, G. C., Haddad, F., Hammond, D., Chien, K., Tang, G., Thakral, B., Montalban-Bravo, G., Pemmaraju, N., Bazinet, A., Swaminathan, M., …, & DiNardo, C. D. (2025). Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. American Journal of Hematology, 100(5), 758-769. https://doi.org/10.1002/ajh.27628
Vancouver
Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia TM, Borthakur G, et al. Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. American Journal of Hematology. 2025;100(5):758-769. doi:10.1002/ajh.27628
BibTeX
@article{Senapati2025,
author = {Senapati, Jayastu and Loghavi, Sanam and Marvin-Peek, Jennifer and Garcia-Manero, Guillermo and Kadia, Tapan M and Borthakur, Gautam and Daver, Naval and Short, Nicholas J and Jain, Nitin and Issa, Ghayas C and Haddad, Fadi and Hammond, Danielle and Chien, Kelly and Tang, Guillin and Thakral, Beenu and Montalban-Bravo, Guillermo and Pemmaraju, Naveen and Bazinet, Alexandre and Swaminathan, Mahesh and Pierce, Sherry and Abbas, Hussein A and Reville, Patrick and Popat, Uday and Shpall, Elizabeth and Champlin, Richard and Jabbour, Elias and Ravandi, Farhad and Kantarjian, Hagop M and DiNardo, Courtney D},
title = {Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {5},
pages = {758--769},
doi = {10.1002/ajh.27628}
}
EUVIMED